辅酶Q10联合血脂康治疗非酒精性脂肪性肝病的临床研究

Clinical effect of silymarin combined with Xuezhikang on non-alcoholic fatty liver disease

目的:观察辅酶Q10联合血脂康治疗非酒精性脂肪肝的疗效。方法:将74例脂肪肝患者随机分入治疗组与对照组,治疗组36例给与辅酶Q10联合血脂康治疗6月。对照组38例使用血脂康治疗6月,治疗前后检查各组血清转氨酶、血脂及肝脏CT等并计算体重指数和胰岛素抵抗指数。结果:辅酶Q10联合血脂康治疗组血清转氨酶、胰岛素抵抗指数及血脂改善明显优于对照组,且差异显著。结论:辅酶Q10联合血脂康治疗非酒精性脂肪性肝病患者具有良好作用。

Objective： To assess the therapeutic effect of coenzyme Q10 combined with Xuezhikang on non-alcoholic fatty liver disease（NAFL）.Methods：patients with NAFL were randomly assigned 36 cases to receive coenzyme Q10 combined with Xuezhikang（6 months） as treatment group.control group 38 cases were treated with Xuezhikang（6 months）.Before and after treatment serum transaminase levels,triglyceride,cholesterol,liver CT,BMI and HOMA-IR etc were detected pre-and pors-treatment.Results： The transaminase,cholesterol and HOMA-IR in treatment group have significantly improve than control group after treatment.Conclusions： coenzyme Q10 combined with Xuezhikang have a significant therapeutic effect on the treatment of NAFL.